Table 7.

Clinical findings in BRPC and LAPC.

Reference	Type of Study	Stage of Disease	Setting	Control Arm	R0 Resection Rate	OS
Versteijne et al. [34]	Meta-analysis	BRPC	NC(R)T	Surgery	88.6% vs. 63.9%, p < 0.0001	Median: 19.2 vs. 12.8 months
Pan et al. [35]	Meta-analysis	BRPC	NC(R)T	Surgery	OR = 4.75 [95% CI, 2.85–7.92]	HR = 0.48 [95% CI, 0.35–0.66]
Janssen et al. [36]	Meta-analysis	BRPC	NCT	NA	83.9%	Median:22.2months [95% CI, 18.8 to 25.6 months]
Chawla et al. [37]	Retrospective	BRPC	NC(R)T	Surgery	NA	Median: 25.7 vs. 19.6 months, p < 0.0001
Jang et al. [38]	Prospective	BRPC	NCRT	Surgery	51.8% vs. 26.1%, p = 0.004	Median: 21 vs. 12 months HR = 1.495 [95% CI, 0.66–3.36]
Versteijne et al. [39]	Prospective	BRPC	NCRT	Surgery	79% vs.13% p < 0.001	HR = 0.62 [95%CI: 0.40–0.95], p = 0.029
Ng et al. [40]	Meta-analysis	LAPC	CRT	CT	NA	Randomized studies: HR = 0.87 [95% CI, 0.63–1.21], p = 0.41 Observational studies: HR = 0.48 [95% CI, 0.35–0.60], p < 0.0001
Huguet et al. [41]	Systematic review	LAPC	CRT	CT	NA	HR = 0.79 [95% CI, 0.32–1.95]
Hammel et al. [42]	Prospective	LAPC	CRT	CT	NA	Median: 15.2 vs. 16.5 months; HR = 1.03 [95% CI, 0.79–1.34] p = 0.83
Zhong et al. [43]	Retrospective	LAPC	CRT	CT	NA	Median: 12.3 vs. 9.8 months HR = 0.79 [95% CI, 0.76–0.83] p < 0.001

Abbreviations: BRPC—Borderline Resectable Pancreatic cancer; CI—confidence interval; CT—chemotherapy; HR—hazard ratio; LAPC—Locally Advanced Pancreatic Cancer; NA—not achieved; NC(R)T—neoadjuvant chemo(radio)therapy; NCT—neoadjuvant chemotherapy; OS—overall survival.